Brooktree Capital Management Has $2.93 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Brooktree Capital Management boosted its position in Pfizer Inc. (NYSE:PFE) by 1.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 89,586 shares of the biopharmaceutical company’s stock after buying an additional 1,572 shares during the quarter. Pfizer makes up about 2.9% of Brooktree Capital Management’s portfolio, making the stock its 12th biggest position. Brooktree Capital Management’s holdings in Pfizer were worth $2,929,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Argus Investors Counsel Inc. grew its stake in Pfizer by 5.3% in the second quarter. Argus Investors Counsel Inc. now owns 108,480 shares of the biopharmaceutical company’s stock valued at $3,547,000 after purchasing an additional 5,500 shares in the last quarter. Monte Financial Group LLC grew its stake in Pfizer by 540.9% during the first quarter. Monte Financial Group LLC now owns 93,388 shares of the biopharmaceutical company’s stock worth $3,048,000 after buying an additional 78,816 shares in the last quarter. Sanders Morris Harris LLC grew its stake in Pfizer by 27.0% during the first quarter. Sanders Morris Harris LLC now owns 31,823 shares of the biopharmaceutical company’s stock worth $580,000 after buying an additional 6,775 shares in the last quarter. First Citizens Bank & Trust Co. grew its stake in Pfizer by 28.3% during the first quarter. First Citizens Bank & Trust Co. now owns 206,716 shares of the biopharmaceutical company’s stock worth $6,747,000 after buying an additional 45,638 shares in the last quarter. Finally, Patriot Financial Group Insurance Agency LLC grew its stake in Pfizer by 21.2% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 15,704 shares of the biopharmaceutical company’s stock worth $514,000 after buying an additional 2,744 shares in the last quarter. 70.20% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have issued reports on PFE shares. ValuEngine downgraded shares of Pfizer from a “hold” rating to a “sell” rating in a research note on Thursday, July 30th. SVB Leerink increased their price objective on shares of Pfizer from $39.00 to $42.00 and gave the stock a “market perform” rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. reduced their price objective on shares of Pfizer from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Monday, June 1st. Piper Sandler increased their price objective on shares of Pfizer from $18.50 to $24.00 in a research note on Friday, June 26th. Finally, Mizuho restated a “buy” rating and issued a $38.00 price target on shares of Pfizer in a research note on Tuesday, July 28th. One analyst has rated the stock with a sell rating, nine have given a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $38.95.

Pfizer stock traded down $0.18 during mid-day trading on Thursday, hitting $38.27. 19,695,096 shares of the stock were exchanged, compared to its average volume of 30,711,830. The company has a quick ratio of 0.78, a current ratio of 1.02 and a debt-to-equity ratio of 0.56. Pfizer Inc. has a 12 month low of $27.88 and a 12 month high of $40.97. The firm’s fifty day simple moving average is $35.24 and its two-hundred day simple moving average is $35.75. The stock has a market capitalization of $212.02 billion, a price-to-earnings ratio of 15.18, a PEG ratio of 3.09 and a beta of 0.74.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.14. Pfizer had a net margin of 28.80% and a return on equity of 25.10%. The firm had revenue of $11.80 billion during the quarter, compared to analyst estimates of $11.55 billion. During the same quarter last year, the business earned $0.80 EPS. The company’s revenue was down 11.0% compared to the same quarter last year. As a group, analysts forecast that Pfizer Inc. will post 2.9 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 31st will be issued a dividend of $0.38 per share. The ex-dividend date of this dividend is Thursday, July 30th. This represents a $1.52 annualized dividend and a yield of 3.97%. Pfizer’s payout ratio is 51.53%.

In other Pfizer news, SVP Jennifer B. Damico sold 2,181 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $36.13, for a total transaction of $78,799.53. Following the completion of the transaction, the senior vice president now owns 7,542 shares in the company, valued at approximately $272,492.46. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.08% of the stock is currently owned by company insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: Trading Options- What is a Strangle?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.